Onconetix (ONCO) Expected to Announce Earnings on Monday

Onconetix (NASDAQ:ONCO) is anticipated to post its Q2 2026 resultson Monday, August 17th. Analysts expect the company to announce earnings of ($4,505.00) per share and revenue of $0.0220 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 9:30 AM ET.

Onconetix Stock Performance

Shares of NASDAQ:ONCO opened at $0.89 on Monday. Onconetix has a 52 week low of $0.67 and a 52 week high of $209.50. The company’s 50 day moving average is $0.95 and its two-hundred day moving average is $19.02. The company has a market cap of $1.02 million, a PE ratio of 0.08 and a beta of 2.69.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ONCO shares. Wall Street Zen downgraded shares of Onconetix from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Onconetix has a consensus rating of “Sell”.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new stake in Onconetix stock. Citadel Advisors LLC purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 1.00% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors and hedge funds.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.